Understanding of the prognostic factors associated with the various forms of induction mortality in patients with acute promyelocytic leukemia (APL) has remained remarkably limited. This study reports the incidence, time of occurrence, and prognostic factors of the major categories of induction failure in a series of 732 newly diagnosed patients with APL of all ages (range, 2 to 83 years) who received ATRA plus idarubicin as induction therapy in two consecutive studies of the PETHEMA Group. Complete remission was attained in 666 patients (91%). All the 66 induction failures were due to induction death. Hemorrhage was the most common cause of induction death (5%), followed by infection (2.3%) and differentiation syndrome (1.4%). Multivariate analysis identified specific and distinct pretreatment characteristics to correlate with an increased risk of death caused by hemorrhage (abnormal creatinine level, increased peripheral blast counts, and presence of coagulopathy), infection (age > 60 years, male gender, and fever at presentation), and differentiation syndrome (ECOG score >1 and low albumin levels), respectively. These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL.
Introduction
Since the routine introduction of all-trans retinoic acid (ATRA) in front-line therapy of acute promyelocytic leukemia (APL), significant improvements in patient outcomes have been achieved. A number of studies conducted over the past decade have contributed to the optimizing of the antileukemic efficacy of ATRA, especially when it is combined with chemotherapy. [1] [2] [3] In fact, the current standard for induction therapy is the simultaneous combination of ATRA with anthracycline-based chemotherapy, which results in extremely high antileukemic efficacy achieving 90 to 95% complete remission (CR) rate. While leukemia resistance to therapy has become an uncommon cause of remission induction failure, death during induction from hemorrhage, infection, and differentiation syndrome (formerly retinoic acid syndrome) has remained the major problem during the early treatment phase. The frequency of induction death from medical complications has probably not changed over recent years. The relative incidence and time of occurrence of each of these categories of induction failure, as well as their pretreatment characteristics (prognostic factors) have been investigated critically and in detail in rare studies only. 4 The present study reports the incidence, time of occurrence, and prognostic factors of the major categories of induction failure in a large series of 739 newly diagnosed patients with APL who received ATRA plus idarubicin (AIDA) 5 as induction therapy in two consecutive studies of the PETHEMA Group (LPA96 and LPA99).
Patients and Methods

Eligibility
Patients enrolled in the consecutive PETHEMA LPA96 and LPA99 trials were required to have a diagnosis of de novo APL with demonstration of the t (15;17) or PML/RARα rearrangements, normal hepatic and renal function, no cardiac contraindications to anthracycline chemotherapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of less than 4. Informed consent was obtained from all patients.
According to the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each participating hospital.
Induction Therapy
Induction therapy consisted of oral ATRA (45 mg/m 2 /d) divided into two daily doses, which was maintained until complete hematologic remission or for a maximum of 90
For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From days, and idarubicin (12 mg/m 2 /d) given as an intravenous bolus on days 2, 4, 6 and 8
(AIDA regimen). For patients 20 years of age or younger, the ATRA was adjusted to 25 mg/m 2 /d. Since November 1999 (LPA99 trial), the dose of idarubicin on day 8 has been omitted for patients older than 70 years of age. Treatment with ATRA was started as soon as a diagnosis of APL was made by morphological criteria. 6, 7 For patients in whom the diagnosis was not confirmed by genetic studies, ATRA treatment was withdrawn and alternative chemotherapy was given at the physician's discretion.
Supportive Measures
Management of coagulopathy. Platelet transfusions were given to maintain a platelet count of more than 30 × 10 with extreme hyperleukocytosis, hydroxyurea and leukapheresis were given at physician discretion. Packed red cell transfusions were recommended to maintain blood hemoglobin greater than 9 g/dL.
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Definitions and Study Endpoints
Remission induction response was assessed according to the recently revised criteria by Cheson et al. 8 A morphologic CR designation requires less than 5% blasts and atypical promyelocytes in an aspirate sample and an absolute neutrophil count of more than 1 × 10 9 /L and platelets of more than 100 × 10 9 /L. Hemoglobin concentration or hematocrit has no bearing on remission status, although the patient must be independent of transfusions. Treatment failure includes those patients for whom treatment has failed to achieve a CR. 
Statistical analysis
The Chi-square test with Yates' correction and Fisher's exact test were used for statistical analyses. P values were calculated using the two-tailed test. Characteristics selected for inclusion in the multivariate analysis were those for which there was some indication of a significant association with induction failure in univariate analysis (P < .1) and, if available, those that prior studies had suggested a possible relationship.
Multivariate analysis was performed using a logistic regression model. 10 Missing data were substituted by the mean values from patients in whom data were available.
11
Computations were performed using the programs from the BMDP statistical library (BMDP Statistical Software Inc, Los Angeles, CA).
Results
Accrual and Patient Characteristics
Between Table 1 .
The main clinical and biologic characteristics of the 732 patients evaluable for induction are shown in Table 2 .
Induction Therapy
Response and induction mortality
Six hundred and sixty-six of the 732 evaluable patients achieved morphologic CR Hemorrhage and infection accounted for most of the deaths during induction therapy (37 and 17 patients, respectively). Differentiation syndrome and acute myocardial infarction were contributing causes of death in 10 and 2 patients, respectively.
Factors Predicting Induction Death
We first set out to evaluate overall induction mortality and in the subsequent sections we evaluated distinct types of death separately, ie hemorrhagic death, infection related death and death associated with the differentiation syndrome respectively.
The univariate analysis of prognostic factors (Table 3) identified the following characteristics predicting induction mortality: older age, with 60 years as the most significant cut-off point (P <.0001), male gender (P = .003), ECOG score 2-3 (P = .01), fever at presentation (P = .02), increased WBC and peripheral blast counts at For personal use only. on October 24, 2017. by guest www.bloodjournal.org From presentation, with 10 x 10 9 /L and 30 x 10 9 /L as the most statistically significant cut-off points, respectively (P < .0001), as well as abnormal levels of serum creatinine (P < .0001), low levels of albumin (P = .003), microgranular subtype (P = .002), and presence of coagulopathy (P = 0.02). After multivariate analysis, the following factors remained as regards their independent predictive significance for induction mortality:
abnormal creatinine level (P < .0001), peripheral blast count of more than 30 x 10 9 /L (P < .0001), age older than 60 (P < .0001), male gender (P = .0006), and WBC count of more than 10 x 10 9 /L (P = .04) ( Table 4) .
Deaths Due to Hemorrhage
Overall, 37 deaths were attributable to hemorrhages. The mortality rates due to hemorrhage were similar in both the LPA96 and LPA99 studies (9/175, 5.1% and 28/561, 5%, respectively), in spite of using tranexamic acid prophylaxis in the latter study. Hemorrhagic mortalities were almost exclusively caused by intracranial (24 patients, 65%) and pulmonary hemorrhages (12 patients, 32%). Of the 24 patients with intracranial bleeding, two developed the hemorrhage over an extensive cerebral thrombosis and two additional patients had concomitant pulmonary hemorrhage. One case of fatal gastrointestinal bleeding was registered. The median time interval from start treatment to develop intracranial and pulmonary hemorrhage was 6 days (range, 1 to 21 days) and 9 days (range 1-23), respectively. Most lethal hemorrhages occurred during the first week (21 patients, 57%). There were 7 deaths (19%) each during the second and third week and 2 (5%) deaths were noted during the fourth week ( Figure   1 ). No lethal hemorrhages were recorded beyond the fourth week. Seventeen out of 24 (71%) cerebral hemorrhages and 4 out of 12 (33%) pulmonary hemorrhages occurred during the first week of starting induction (P = .07). Twenty-five of 36 patients (69%) who died from cerebral (19/24) or pulmonary hemorrhages (6/12) had a fulminant course, with death occurring within 24 hours from the onset of lethal bleeding.
Factors Predicting Fatal Hemorrhage
The univariate analysis (Table 3) /L as the most statistically significant cut-off points, respectively (P < .0001), as well as abnormal levels of serum creatinine (P < .0001) and presence of coagulopathy (P = 0.01), whereas there was a trend for microgranular subtype (P = .09) and short
PML/RARα isoform (bcr3) (P = .09). After multivariate analysis, the following factors remained significant: abnormal creatinine level (P < .0001), peripheral blast count of more than 30 x 10 9 /L (P = .0006), and presence of coagulopathy (P = 0.03) ( Table 4) .
Deaths Due to Infection
Overall, 17 deaths were attributable to infection. Infection-associated mortality was due to pneumonia (9 patients, 53%), septicemia (6 patients, 35%), orbital cellulitis (n = 1) and clinically and radiologically suspected, but not microbiologically documented 
Factors Predicting Fatal Outcome of Infection
The following prognostic factors (Table 3 ) with respect to infectious mortality appeared from univariate analysis: older age, with 60 years as the most significant cut-off point (P < .0001), male gender (P = .02), fever at presentation (P = .01), and abnormal serum creatinine level (P = .04). Among these, multivariate analysis identified the following independent prognostic parameters: age older than 60 years (P < .0001), male gender (P = .003), and fever at presentation (P = .009) ( Table 4) .
Deaths Due to Differentiation Syndrome
Ten deaths attributable to DS occurred at a median of 17 days of starting induction (range, 1 to 26). The time of occurrence of deaths due to DS is shown in Figure 2 . The mortality rates due to DS were similar in both the LPA96 and LPA99 studies (1.1% and 1.4%, respectively), in spite of prednisone prophylaxis in the latter. Renal and respiratory failures, either combined or separately, were implicated in all deaths (8 combined, 1 renal and 1 respiratory failure). Two patients underwent hemodialysis, two mechanical ventilation, and three both procedures.
Factors Predicting Fatal Outcome of DS
The following prognostic factors (Table 3 ) correlated with death associated with DS following univariate analysis: ECOG score 2-3 (P = .01), low level of albumin (P = .02), whereas there was a trend for younger age, with 15 years as the most significant cutoff point (P = .08). Multivariate analysis identified ECOG score ≥ 2 and low level of albumin (P = .045) as the only significant independent prognostic factors ( Table 4) .
Other causes of death
In absence of history of cardiac events and coronary risk factors, two male patients of 65 and 68 years of age developed a fatal acute myocardial infarction at days 15 and 33 of induction therapy, respectively. Both were diagnosed by chest pain consistent with ongoing myocardial ischemia with concomitant typical changes in electrocardiogram and creatine kinase levels.
Discussion
Remission induction deaths continue to represent one of the major stumbling blocks in modern therapy of APL. This study shows that hemorrhage is the single most common cause of death (5%) during induction therapy, followed by infection (2.3%) and differentiation syndrome (1.4%) in patients with APL receiving ATRA and idarubicin (AIDA regimen). Typically, the majority of lethal hemorrhages occurred early during induction, whereas infection and DS caused deaths at a somewhat later time.
Multivariate analysis identified pretreatment characteristics associated with an increased risk of death, which were different to predict fatal hemorrhage (abnormal creatinine level increased peripheral blast counts, and presence of coagulopathy), death due to infection (age older than 60 years, male gender, and fever at presentation), and death due to DS (ECOG score ≥ 2 and abnormal albumin levels).
Thus, apparently these different types of death seem subject to different and specific risk factors. This may provide clinically relevant information that in the future may be useful for designing more appropriately risk-adapted treatment protocols and improving treatment outcome in this type of leukemia.
A number of studies conducted over the last decade have contributed to the optimizing of the antileukemic efficacy of ATRA when used in combination with anthracyclinechemotherapy for induction therapy. [1] [2] [3] In fact, this combination shows an extremely high antileukemic efficacy, leading to complete remission rates in 90 to 95% of cases and leukemia resistance has been only reported in infrequent cases. 4, [12] [13] [14] For personal use only. on October 24, 2017. by guest www.bloodjournal.org From It should be noted that four of the six non evaluable patients who were registered by their physicians in our study as resistant leukemia, and then administered salvage therapy, had developed a definitely present DS and all of them were assessed prematurely for response, i.e. during pancytopenia. This is contradictory to the current recommendations of response assessment in APL. 8 Unfortunately, the hasty administration of salvage therapy to all these patients with delayed clearance of blasts did not allow us to verify whether or not they were really chemotherapy resistant or rather only exhibited a delay in terminal differentiation of blasts. In case of any doubt about the achievement of CR, it is recommended to repeat another BM assessment after an additional interval of 2-3 weeks, and meanwhile refrain from new therapeutic interventions. Since the introduction of this policy, no case of resistant leukemia has been recorded among the most recent 350 patients enrolled in the PETHEMA studies.
Apart from a virtual absence of leukemia resistance and a lower mortality rate observed in APL as compared to other subtypes of AML, the causes of induction deaths showed a characteristic pattern and time of occurrence that also differ from those in AML. In addition to an increased WBC count, which has been recognized as independent prognostic factor of response to induction therapy in other studies, [12] [13] [14] 20 we also found that the presence of coagulopathy and abnormal levels of creatinine were significantly associated with a higher risk of mortality and, most particularly, of hemorrhagic mortality during induction remission. It should be noted that the inclusion of peripheral blast counts in multivariate analysis, which has been also recognized as independent
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From prognostic factor of early death (defined as death occurring within the first 10 days of induction treatment) by the Italian GIMEMA group, 4, 17 prompted that WBC count was removed from the regression model. The reason for the association between an elevated creatinine value and death from hemorrhage is not clear, although one may speculate that it might be a reflective sign of the disseminated intravascular coagulopathy compromising the glomerular microcirculation. However, this speculation is apparent contrast the presence of coagulopathy as an independent prognostic factor.
Whatever the explanation, it may also be noted that an abnormal level of creatinine was already found to predict poor response to induction therapy in a study reported by us in the pre-ATRA era. 21 The prognostic value of the hemorrhagic score defined by the GIMEMA group, 22 and also recognized as independent prognostic factor, 4 was not analyzed in the present study because clinical assessment of our patients did not include the use of this score.
It should be noted that the reported hemorrhagic mortality was observed in spite of a generalized and early aggressive supportive care given to all patients, regardless of prognostic factors. In this context, the acknowledgment of a particular set of prognostic factors can be useful to identify very high-risk patients as potential target population to explore experimental or novel approaches in order to minimize the risk of death due to hemorrhage. With regard to the systematic use of tranexamic acid prophylaxis in the LPA99 trial, an historical comparison with the LPA96, without tranexamic acid prophylaxis, showed no impact in decreasing hemorrhagic mortality. However, there was a trend toward a higher incidence of thrombosis. 23 Therefore, a potential benefit of the use of tranexamic acid in this setting is not supported by this study.
The type of infections associated with mortality in the present study appears similar to that seen during induction therapy in AML. However, the incidence of infectious deaths (2.3%) was lower than generally reported in other subtypes of AML. Apart from the apparently shorter time to haematological recovery in APL compared to AML, the relatively low median age of patients and the lack of use of cytarabine, among others, might explain the low infectious mortality rate observed in our series. As far as we know, a study of prognostic factors of remission failure due to infection in APL has not been reported previously. Although age is generally recognized as a risk factor of death during induction therapy due to the greater 'vulnerability' to chemotherapy toxicity of older patients, we have found two additional factors that contribute to a higher risk of infection-related death, i.e. male gender and fever at presentation. It is presently unclear why we observed a lower mortality among women. We can speculate on a better tolerance to the side effects of chemotherapy linked to better organ function in
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From female patients, particularly at older age, which would be in line with the somewhat greater life expectancy of women in general. This factor was already noted in a previous study of our group concerned with elderly patients. 24 The greater risk of death due to infection that was apparent in patients presenting with fever at time of diagnosis may be related with an intrinsic susceptibility to infections but also to a more prolonged use of antibiotics leading to a higher risk of breakthrough bacterial and fungal infections.
It should be noted that the characteristics predisposing to lethal DS, such as ECOG ≥ 2 and low levels of serum albumin, should be cautiously interpreted due the low number of events observed (10 out of 733 patients at risk). These characteristics were not recognized as independent prognostic factors of remission failure, probably due to the low contribution of DS-associated mortality upon the overall mortality. In this regard it is also of note that the systematic use of prednisone prophylaxis in the LPA99 trial,
showed no impact on reducing mortality due to DS as compared to a selective use of dexamethasone prophylaxis in patients with more than WBC count greater than 5 × In summary, our study of a large series of patients homogeneously treated for induction with ATRA and idarubicin shows a characteristic pattern of causes of induction failure, as well as a specific set of prognostic variables that can be applied to predict separate types of induction failure. These predictive models, based on readily available baseline characteristics, may be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing mortality from hemorrhage, infection, or DS. Post-stroke hemiplegia 1
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